Enamine expands collaboration with Europe’s largest biopharmaceutical company
Extends multi-year agreement in drug discovery with focus on cardiovascular and central nervous system disorders, immunology, infectious diseases and oncology.
Enamine has agreed to expand its collaboration in early drug discovery with Actelion Pharmaceuticals (Actelion). Enamine is providing library synthesis and medicinal chemistry services through application of the company’s extensive capabilities for the synthesis of advanced screening compound libraries. The collaboration is focused on therapeutic areas including cardiovascular and central nervous system disorders, immunology, infectious diseases and oncology.
The two companies began working together in 2005 and the collaboration has grown due to the increased demand for building blocks for drug discovery. With the world’s largest stock of chemical compounds and services, Enamine has become an important supplier at Actelion. Enamine’s unique building blocks have gained recognition at Actelion and led to the signing of contracts in exclusive library synthesis for internal archive enrichment and lead compound generation.
Under the terms of the expanded agreement, scaffold compounds supplied by Actelion will be decorated with building blocks selected from the Enamine collection to generate exclusive screening compounds by Enamine. In addition, the companies have entered, under a separate contract, into a Full Time Equivalent (FTE) based research agreement, whereby Enamine will actively support Actelion’s medicinal chemistry efforts. The Enamine database of building blocks has been integrated into Actelion’s IT platform for optimizing the access, ordering and delivery time of any structure necessary for Actelion’s global research projects.
Christoph Boss, Senior Director, Chemistry Technologies and Lead Discovery at Actelion, explained: “Enamine is very well positioned among chemical CROs. Their screening compound libraries have always been highly regarded in hit-finding projects at Actelion because of their diversity and quality. The combination of Enamine’s large library of building blocks, their synthesis skills and technologies, as well as the excellent level of trust we have built over the years, makes the collaboration very attractive for Actelion. We are happy to be extending our collaboration and I look forward to reaching our next milestones.”
Michael Bossert, Head of Strategic Alliances at Enamine, said: “We have worked extensively with Actelion over the years, and we are delighted to be entering into further new areas of collaboration with such a leading pharmaceutical company. We see this as another example of Enamine’s technical and servicing expertise for optimizing and advancing our customer’s early discovery research projects. This announcement is the conclusion of another year of great successes and achievements at Enamine, ultimately working toward the launch of life changing medicines by its customers.”
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance